GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology.
Mediocre balance sheet and slightly overvalued.
Share Price & News
How has GenMark Diagnostics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GNMK's share price has been volatile over the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: GNMK underperformed the US Medical Equipment industry which returned -5% over the past year.
Return vs Market: GNMK underperformed the US Market which returned -10.4% over the past year.
Price Volatility Vs. Market
How volatile is GenMark Diagnostics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StIs GenMark Diagnostics, Inc. (NASDAQ:GNMK) Trading At A 27% Discount?
3 weeks ago | Simply Wall StGenMark Diagnostics, Inc. Annual Results Just Came Out: Here's What Analysts Are Forecasting For Next Year
1 month ago | Simply Wall StThis Insider Has Just Sold Shares In GenMark Diagnostics, Inc. (NASDAQ:GNMK)
Is GenMark Diagnostics undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GNMK ($4.06) is trading below our estimate of fair value ($6.95)
Significantly Below Fair Value: GNMK is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GNMK is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: GNMK is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GNMK's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GNMK is overvalued based on its PB Ratio (20.1x) compared to the US Medical Equipment industry average (3.1x).
How is GenMark Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GNMK is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GNMK is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GNMK is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GNMK's revenue (16.2% per year) is forecast to grow faster than the US market (7.2% per year).
High Growth Revenue: GNMK's revenue (16.2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GNMK's Return on Equity is forecast to be low in 3 years time (16.2%).
How has GenMark Diagnostics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GNMK is currently unprofitable.
Growing Profit Margin: GNMK is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GNMK is unprofitable, and losses have increased over the past 5 years at a rate of -5.3% per year.
Accelerating Growth: Unable to compare GNMK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GNMK is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: GNMK has a negative Return on Equity (-389.3%), as it is currently unprofitable.
How is GenMark Diagnostics's financial position?
Financial Position Analysis
Short Term Liabilities: GNMK's short term assets ($83.4M) exceed its short term liabilities ($24.3M).
Long Term Liabilities: GNMK's short term assets ($83.4M) exceed its long term liabilities ($75.0M).
Debt to Equity History and Analysis
Debt Level: GNMK's debt to equity ratio (568.5%) is considered high.
Reducing Debt: GNMK's debt to equity ratio has increased from 0.1% to 568.5% over the past 5 years.
Inventory Level: GNMK has a high level of physical assets or inventory.
Debt Coverage by Assets: GNMK's debt is covered by short term assets (assets are 1.2x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GNMK has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if GNMK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is GenMark Diagnostics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GNMK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate GNMK's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GNMK's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GNMK's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GNMK's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Scott Mendel (52yo)
Mr. Scott Mendel has been the Chief Operating Officer at GenMark Diagnostics, Inc. since February 18, 2019 and has its Interim President and Chief Executive Officer since February 10, 2020. Mr. Mendel serv ...
CEO Compensation Analysis
Compensation vs Market: Scott's total compensation ($USD1.28M) is about average for companies of similar size in the US market ($USD1.49M).
Compensation vs Earnings: Scott's compensation has been consistent with company performance over the past year.
|COO, Interim President & CEO||no data||US$1.28m||0.41% $1.0m|
|Senior Vice President of Corporate & Strategic Accounts||6yrs||US$967.56k||0.67% $1.7m|
|Senior VP of Operations||no data||US$943.18k||0.42% $1.0m|
|Chief Financial Officer||1yr||no data||0.44% $1.1m|
|Senior VP||6.83yrs||US$829.12k||0.20% $500.4k|
|Senior Vice President of Sales||0.83yr||no data||no data|
Experienced Management: GNMK's management team is considered experienced (3.5 years average tenure).
|Non-Executive Director||10yrs||US$156.00k||0.14% $353.8k|
|Non-Executive Director||5yrs||US$145.00k||0.17% $409.6k|
|Non-Executive Director||9.42yrs||US$237.98k||0.36% $880.2k|
|Chairman of the Board||no data||US$166.00k||0.13% $323.7k|
|Non-Executive Director||5yrs||US$150.00k||0.076% $188.0k|
Experienced Board: GNMK's board of directors are considered experienced (7.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: GNMK insiders have sold more shares than they have bought in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.5%.
GenMark Diagnostics, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: GenMark Diagnostics, Inc.
- Ticker: GNMK
- Exchange: NasdaqGM
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$246.750m
- Shares outstanding: 60.78m
- Website: https://www.genmarkdx.com
Number of Employees
- GenMark Diagnostics, Inc.
- 5964 La Place Court
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|GNMK||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||May 2010|
|GNF||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||May 2010|
|0IUT||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||May 2010|
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/03/31 03:09|
|End of Day Share Price||2020/03/30 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.